Topics
Meeting category
Date(s)
9 May 2023 - 12 May 2023
Program Language
English, French, Portuguese
Location
Maputo,
Mozambique
Meeting type
In-Person Meeting
INTEREST 2023
Related Enduring Materials
Enduring Materials
The presentation videos and slides for speakers’ lectures are made available, provided that they have granted us permission to do so.
Session 1: Official Opening Ceremony -
Speech by H.E. Ambassador of PEPFAR
The Road to 95-95-95: Progress in HIV Prevention and Treatment Scale-up in Sub-Saharan Africa
Session 2: Emerging and Re-emerging Diseases I: James Hakim Memorial Lectures -
Lucille H Blumberg, MB, BCH, MMed (Clin Micro), ID (SA), FFTM (RCP Glasgow), DTM&H, DOH, DCH, D.Sc.
Nafiisah Chotun, PhD, FRSPH, MRSTMH
Emerging and Re-emerging Diseases: Role of Surveillance
National Institute for Communicable Diseases / Right to Care, South Africa
The Strategic Role of the Africa CDC in Emerging and Re-Emerging Diseases in Africa
Africa Centres for Disease Control and Prevention (Africa CDC), Ethiopia
Long Covid: Pathophysiology, Presentation, and Management
Session 3: Emerging and Re-emerging Diseases II -
Sikhulile Moyo, MSc, MPH, PhD
Jean B. Nachega, MD, PhD, MPH, FRCP, FAAS
COVID-19 Variants and Implication for Vaccination
Botswana Harvard AIDS Institute Partnership / Harvard T.H. Chan School of Public Health, Botswana
COVID-19 and Pregnancy and Neonatal Outcomes
University of Pittsburgh / Johns Hopkins University, United States Stellenbosch University, South Africa
Session 4: Opening Day Formal Debate: The UNAIDS Fast Track “95-95-95” HIV Treatment Goal by 2030 is Unrealistic for Children Living with HIV -
Nadia Sam-Agudu, MD, CTropMed
Nadia Sam-Agudu, MD, CTropMed
First Speaker For the Proposition
University of Minnesota / Institute of Human Virology Nigeria, United States / Nigeria
First Speaker Against the Proposition
Second Speaker For the Proposition
Second Speaker Against the Proposition
Rebuttal
University of Minnesota / Institute of Human Virology Nigeria, United States / Nigeria
Session 5: HIV Prevention and Cure -
New HIV Prevention Technologies
Advances in HIV Cure Science
HIV Vaccines, Where Are We Now?
Industry Symposium I | ViiV: I Am Not A Statistic, Hear Me: Voices of Young People Living With HIV -
Young People Should be Partners in their Healthcare
Nneka Nwokolo, FRCP
ViiV Healthcare / Chelsea and Westminster Hospital, United Kingdom
Sibulele Sibaca Nomnganga, BA, GIBS
Impact Drivers, South Africa
Sunflower Nyemba
Young People’s Network on Sexual and Reproductive Health, HIV and AIDS (YPNSRHHA), Zimbabwe
Session 6: HIV and Adolescents -
Rashida Ferrand, FRCP, PhD, FMed Sci
Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD
HIV-Associated Neurocognitive Disease Among Adolescents
London School of Hygiene & Tropical Medicine, United Kingdom / Biomedical Research and Training Institute, Zimbabwe
Reaching Adolescent Girls and Young Women: What Interventions Work?
Desmond Tutu Health Foundation / University of Cape Town (UCT), South Africa
Session 7: Elimination of Vertical Transmission and HIV in Children -
Mogomotsi Matshaba, MD, MB BCh BAO, BMedSci (Hons)
Eliminating Vertical HIV Transmission - Are We There Yet?
Where Are the Missing Children: Closing the Paediatric HIV Gap
Aiming for Gold - The Botswana Quest for Elimination of Vertical Transmission of HIV
Baylor College of Medicine, United States / Botswana-Baylor Children’s Clinical Centre of Excellence, Botswana
Special Session I - World Health Organization: Hands-on Session: How to Effectively Use WHO Resources to Boost R&D Efforts Programme -
Introduction to R&D Support at WHO and Perspective on Why It Matters
Anna Laura Ross, PhD
World Health Organization, Switzerland
Hands on Session with International Clinical Trials Registry Platform: What Trials are Being Performed Where and By Who
Anna Laura Ross, PhD
World Health Organization, Switzerland
Hands on Session with Global Observatory on Health R&D: Finding Resources and Collaborators
Sarah Charnaud, PhD
World Health Organization, Switzerland
Anna Laura Ross, PhD
World Health Organization, Switzerland
Session 8: HIV Care and Treatment -
Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications
HIV Drug Resistance and Treatment Sequencing
Symposium IV | CIDRZ: Africans Leading the HIV Response: Pipe Dream or Reality -
Africans Leading the HIV Response: Pipe Dream or Reality
Yvette Raphael
Advocates for the Prevention of HIV in Africa, South Africa
Session 9: HIV and Comorbidities I: TB and Hepatitis -
Lloyd Mulenga, BScHB, MBChB, MSc, MMed, PhD
What’s New in the Treatment of Rifampin Resistant TB
Use of TAF in TB and Hepatitis Co-infected Patients: Lessons to Date
Ministry of Health / University Teaching Hospital, Zambia
Session 10: HIV and Comorbidities II: HIV and HPV -
Sabrina Bakeera-Kitaka, MD, PhD
Lloyd Mulenga, BScHB, MBChB, MSc, MMed, PhD
Progress of HPV Vaccination Introduction in Africa
Makerere University College of Health Sciences / Mulago National Referral Hospital, Uganda
Integration of HPV Prevention in HIV Care
Ministry of Health / University Teaching Hospital, Zambia
Session 11 HIV and Comorbidities III: Aging, NCDs, and Mental Health -
Primrose Nyamayaro, BSc (Hons), MRes, PhD
HIV and Aging in Sub-Saharan Africa
HIV and Mental Health: Innovations from Zimbabwe
University of Zimbabwe Faculty of Medicine and Health Sciences, Zimbabwe
Special Session II UNITAID - Clinical Trials in Africa: Lessons & Recommendations from the TRIO and D2EFT Trials -
Loice Achieng Ombajo, MBChB, MMED
Why Clinical Trials Matter in LMICs
University of Nairobi/University of Texas Medical Branch, Kenya/United States
Perspectives
Next Phase of ART Optimisation
Mini-Oral Abstract Presentations V -
Empowered by Faith to Leave No One Behind: Collaborating with Faith- Based Organizations to Deliver HIV Services to Men in Zambia (#30)
La Peur Persistante de la Stigmatisation : Principal Obstacle à la Décentralisation de la Prise en Charge du VIH Pédiatrique AU Sénégal (#31)
High Prevalence of Anal Oncogenic Human Papillomavirus Infection in Young Men Who Have Sex with Men Living in Bamako, Mali (#32)
Challenges With Oral PrEP Uptake, Condom and ART Use Among Female Sex Workers in Three Districts in Malawi - Results From Recent HIV Infection Surveillance Hotspot Investigations (#33)
Access to Cervical Cancer Screening Among Women Living With HIV in Malawi - Analysis of Malawi Population-Based HIV Impact Assessment (MPHIA) 2020-21 and MPHIA 2015-16 Surveys (#34)
Session 12: Addressing Structural Barriers & Key Populations -
Gender and HIV in Africa
Addressing HIV Stigma Alone Is Not Enough: Institutional and Structural Support for Healthcare Workers
Sustaining the Efforts Towards Achieving HIV Epidemic Control Among Key Populations in Africa
Session 13 Health Systems Strengthening -
MATRIX: Building Affordable, Acceptable, and Sustainable HIV Prevention Products for LMICs
Access to Medicine
Mini-Oral Abstract Presentations VI -
Preliminary Results of Safety in Health Care Workers After the BBIBPCorV Vaccine in Mozambique (#35)
Hybrid Immunity in Mozambican Healthcare Workers Vaccinated With an Inactivated COVID-19 Vaccine (#36)
Positive and Healthy Living Program for Young People Living With HIV in Nairobi, Kenya: Findings From a Pilot Study (#37)
Risk Compensation Among Virally Suppressed Persons on Anti- Retroviral Therapy (#38)
Complexities of Managing Survivors of Gender-Based Violence; Experiences From Beitbridge, Zimbabwe (#39)
Industry Symposium V | Johnson and Johnson: Sunrise in Long-Acting ART Era – A New Chapter in Our Lives -
Challenges and Opportunities for Transitioning to the Clinical Use of LA ART
Experience in Implementing LA ART in Adolescent HIV Program – Providers and Youth Perspectives
General
What's New
-
To stay updated on the relevant developments, make sure you are signed up for our newsletter.
Official Conference Website
Welcome
INTEREST 2023 successfully took place from 9-12 May 2023 as a live meeting in Maputo, Mozambique.
The annual INTEREST Conference is the premier scientific conference for HIV in Africa, and brings together scientists involved in HIV treatment, pathogenesis, and prevention research from around the world. The conference showcases cutting-edge knowledge in the diagnosis and treatment of HIV and the prevention of HIV-1 acquisition. It continues to foster a community of African physicians and scientists to facilitate the implementation of local solutions for the management of people living with HIV and for the prevention of HIV transmission.
INTEREST is co-organised by Amsterdam Institute for Global Health and Development (AIGHD) and Virology Education.
Conference Chairs
Local Co-Chairs
General Information
Past Conferences
2007 – Kampala, Uganda
2008 – Dakar, Senegal
2009 – Lusaka, Zambia
2010 – Maputo, Mozambique
2011 – Dar Es Salaam, Tanzania
2012 – Mombasa, Kenya
2013 – Dakar, Senegal
2014 – Lusaka, Zambia
2015 – Harare, Zimbabwe
2016 – Yaounde, Cameroon
2017 – Lilongwe, Malawi
2018 – Kigali, Rwanda
2019 – Accra, Ghana
2020 – Windhoek, Namibia (Virtual Conference)
2021 – Virtual Conference
2022 – Kampala, Uganda
2008 – Dakar, Senegal
2009 – Lusaka, Zambia
2010 – Maputo, Mozambique
2011 – Dar Es Salaam, Tanzania
2012 – Mombasa, Kenya
2013 – Dakar, Senegal
2014 – Lusaka, Zambia
2015 – Harare, Zimbabwe
2016 – Yaounde, Cameroon
2017 – Lilongwe, Malawi
2018 – Kigali, Rwanda
2019 – Accra, Ghana
2020 – Windhoek, Namibia (Virtual Conference)
2021 – Virtual Conference
2022 – Kampala, Uganda
Abstract Submission
The Abstract Submission Portal for INTEREST 2023 is now closed.
Practical Information
Badges
All participants are requested to wear their badge at all times during the conference to ensure admission to the meeting.
Certificate of Attendance
A certificate of attendance will be sent to participants that have successfully completed the post-conference survey.
Language
The official language of the conference is English. French and Portuguese translation will be available.
Conference Materials
Conference materials can be obtained upon registration at the registration desk at the Conference Venue.
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the conference, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance.
Participants are advised to take out their own insurance policies.
Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Support
Gold Level
Bronze Level
Prime Supporter
Support Our Initiative
Financial backing helps us deliver an impactful meeting experience for the benefit of healthcare professionals and community representatives involved in HIV treatment, pathogenesis, and prevention research.
This collaboration plays a vital role in both the organisational as well as scientific success of the programme.
To show your commitment to the cause and get in touch with us for a tailored support package, please contact either
Karin Siebelt at Karin.Siebelt@amededu.com or call +31 30 230 7147, or
Marloes Nijboer at m.nijboer@aighd.org
Benefits of Support
By supporting this programme, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this programme.
- Symposium opportunities
- Non-commercial interviews with company representatives
- Verbal acknowledgement during the programme
- Discounted and complimentary registrations for your representatives
- Company acknowledgement on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
- Company acknowledgement on printed meeting materials including but not limited to banners and the programme book
- Digital and printed advertising opportunities
- Social media shout-outs
- Logo on the conference bag
*Subject to the support level.
Media
INTEREST 2022
AIDSMap reviewed the INTEREST 2022 Conference, highlighting sessions such as those on global health targets, vaginal rings & topical PrEP, HIV treatment in pregnancy, and more.
Read their article here.
Language
Related Programs
